Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Hims & Hers Health's 3-1 Month Momentum % is 34.26%.
The industry rank for Hims & Hers Health's 3-1 Month Momentum % or its related term are showing as below:
HIMS's 3-1 Month Momentum % is ranked better than 91.26% of 1030
companies
in the Drug Manufacturers industry
Industry Median: -8.59
vs HIMS: 34.26
Hims & Hers Health (NYSE:HIMS) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Hims & Hers Health 3-1 Month Momentum % Related Terms
HIMS vs LNTH, AMRX, LQDA: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's 3-1 Month Momentum % falls into.
Hims & Hers Health (NYSE:HIMS) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (HIMS) has a 3-1 Month Momentum % of 34.26% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Hims & Hers Health and its competitors. According to the industry distribution chart, Hims & Hers Health ranks #90 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 8.7%.
Is Hims & Hers Health's 3-1 Month Momentum % too high?
Hims & Hers Health's current 3-1 Month Momentum % is 34.26%. Based on the distribution chart, Hims & Hers Health ranks #90 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hims & Hers Health has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's 3-1 Month Momentum % compare to LNTH and AMRX?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #90 out of 1030 companies for 3-1 Month Momentum %. This places Hims & Hers Health in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Hims & Hers Health and its competitors. Hims & Hers Health's current 3-1 Month Momentum % is 34.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is $40.57, compared to a current price of $30.82 — trading 24% below its estimated fair value. The current 3-1 Month Momentum % is 34.26%. Hims & Hers Health's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current 3-1 Month Momentum % is 34.26% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of $30.82 is trading 24% below its estimated GF Value™ of $40.57.
GuruFocus considers Hims & Hers Health to be Modestly Undervalued.
Key valuation signals for HIMS:
3-1 Month Momentum %: 34.26%
GF Value™: $40.57 vs. price of $30.82 (24% below fair value)
No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
78GF Score
Get the complete analysis for HIMS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIMS has been successfully added to your 
